Mobic
Mobic is a once-daily, 7.5 mg tablet indicated for the relief of the pain and stiffness associated with osteoarthritis. Mobic is a non-steroidal anti-inflammatory drug (NSAID).
Osteoarthritis is a disease which affects approximately 80% of Americans over the age of 65. The disease, which causes the cartilage in the joints to break down, is especially painful and debilitating.
General Precautions with Mobic:
Do not stop taking any medications that you have been prescribed without first talking to your health care provider.
Serious problems such as liver damage have occurred in people treated with NSAIDs. Some of the warning signs of liver damage can be nausea, vomiting, fatigue, loss of appetite, itching, yellow coloring of skin or eyes, "flu-like" symptoms and dark urine. If you experience any of these symptoms, call your health care provider right away.
Mobic side effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop taking Mobic and seek medical attention or call your doctor at once if you have any of these serious side effects: chest pain, weakness, shortness of breath, slurred speech, problems with vision or balance; black, bloody, or tarry stools, coughing up blood or vomit that looks like coffee grounds; urinating less than usual or not at all; nausea, stomach pain, low fever, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); fever, sore throat, and headache with a severe blistering, peeling, and red skin rash; bruising, severe tingling, numbness, pain, muscle weakness.
Pauciarticular and Polyarticular Course Juvenile Rheumatoid Arthritis
MOBIC oral suspension is available in the strength of 7.5 mg/5 mL. To improve dosing accuracy in smaller weight children, the use of the MOBIC oral suspension is recommended. For the treatment of juvenile rheumatoid arthritis, the recommended oral dose of MOBIC is 0.125 mg/kg once daily up to a maximum of 7.5 mg. There was no additional benefit demonstrated by increasing the dose above 0.125 mg/kg once daily in these clinical trials.
Drug Interactions
Furosemide. Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Studies with furosemide agents and meloxicam have not demonstrated a reduction in natriuretic effect. Furosemide single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of meloxicam. Nevertheless, during concomitant therapy with MOBIC tablets/oral suspension, patients should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.
Storage instructions
Store at room temperature in a tightly closed container. Keep away from moisture.
